Frostbite

Mark Mitchell, Co-Founder & General Partner at Weave VC
  • 0.0 (0)
  • Emprendimiento

Welcome to Frostbite. Join us as we uncover valuable insights from Canada’s top technology investors, leaders, and innovators. Hosted by Weave VC Co-founder & General Partner, Mark Mitchell. Check out our blog: https://medium.com/@weave.vc Follow us on LinkedIn: https://www.linkedin.com/company/7710458 Connect with us on X: https://twitter.com/WeaveVC

  1. 18/09/2023

    Startup Fundraising with Chris Robson, CEO & Co-founder at Wyvern

    We had a chance to sit down with our friend Chris Robson for a deep dive into startup fundraising. Chris is the CEO & Co-founder at Edmonton based Wyvern, a space data company enabling next-generation earth observation using hyper-spectral cameras. If you're an entrepreneur thinking about that first raise, be sure to listen in as Chris shares some of his learnings after successfully raising $17.M in capital from some of North America's top seed investors including MaC Venture Capital, Uncork Capital, Y-Combinator, and Soma Capital. We were fortunate enough to participate in Wyvern's early rounds of financing through our angel syndicate Red Thread Ventures and our venture capital firm Weave VC and have been amazed at their progress over the past few years! For more information on Wyvern and their offerings, please visit them online at https://wyvern.space/

    1 h 2 min

  2. 23/05/2023

    Journey to human clinical trials: Early-stage therapeutics development with Dr. Mads Daugaard

    Today’s guest is Dr. Mads Daugaard. Mads is the Co-founder, President and Chief Scientific Officer at Canadian cancer therapeutics company, Rakovina Therapeutics, a Red Thread Ventures portfolio company. This is his third time on our podcast and in today’s session we focused on Rakovina’s 2022 progress, their partnership with the St.Baldrick's foundation, distinctions between first generation/next generation therapies, and their push to IND filing and human clinical trials. We hope you enjoy today’s discussion with Dr. Mads Daugaard! Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information can be found at www.rakovinatherapeutics.com, on LinkedIn, and on Twitter @rakovina_rkv. Red Thread Ventures has featured Rakovina in multiple blog posts, head over to www.redthread.ventures/blog to learn more.

    39 min

  3. 29/04/2022

    Cancer Research and Novel DNA Repair Inhibitors with Mads Daugaard

    Dr. Mads Daugaard is the Co-founder, President and Chief Scientific Officer at biotech company, Rakovina Therapeutics. Founded in 2020, Rakovina is striving to revolutionize cancer treatment and extend the lives of cancer patients. Not yet in human clinical trials, they are developing medicines that selectively target and kill cancer cells using leading-edge science that we’ll discuss with Mads in this episode. The therapeutics company has 3 research programs, Kt-2000, 3000 and 4000, all of which are in the preclinical stage of drug development. Rakovina is currently being traded on the TSX Venture Exchange under the symbol RKV. On April 8th in New Orleans, Mads is attending the American Association for Cancer Research or AACR annual meeting, which is the largest cancer research conference.  Following that he is sharing an abstract highlighting Rakovina’s KT-3000 series at AACR’s special conference on Sarcoma cancer in Montreal. The episode highlights why it is so important for Rakovina and other preclinical biotech companies to attend conferences like these.  To learn more about Rakovina's presentation at the AARC conference, you can view their press release here. To continue your dive into biotech investing, check out this blog series featuring Rakovina: Myths and Risks in Biotech Investing Rakovina Therapeutics Website  LinkedIn  Twitter Red Thread Ventures  Website LinkedIn  Youtube

    43 min

  4. 30/11/2021

    Biotech Innovation with Mads Daugaard

    On today's episode, we sit down with Doctor Mads Daugaard, the President and Chief Scientific Officer at Rakovina Therapeutics. Mads is a molecular biologist who earned his PhD degree from the Faculty of Health Sciences, University of Copenhagen, for his studies on heat shock proteins in relation to cancer cell survival mechanisms. He is also Head of the Molecular Pathology and Cell Imaging Unit, Senior Research Scientist at Vancouver Prostate Centre, and associate Professor at Department of Urologic Sciences, University of British Columbia.  Check out this episode to learn more about biotech industry, preclinical research, and the impressive waves that Rakovina Therapeutics are creating in the oncology space.

    39 min

  5. 14/09/2021

    International Business & Networking with Mark Mitchell

    On today's episode, we sit down with Mark Mitchell, the Principle and Director of Red Thread Ventures, the investment firm where we work; Mark is also the Co-Founder at IPEX. Mark has had the pleasure of travelling around the world and building connections, while simultaneously building up his portfolio of experiences. More specifically, he has immersed himself with business in China (he is even fluent in Mandarin too!). Through our conversation, we learn more about the benefits of conducting business internationally as well as the Dos and Don'ts of networking. Mark's tips apply to everyone, whether you are a student or a seasoned professional, so you won't want to miss it!

    43 min

  6. 19/08/2021

    Fundamentals-Based Investing with Xin Zheng

    We have an expected guest for today's episode, Xin Zheng, otherwise known as Prof X to us. Prof X was our financial accounting professor this summer and is a passionate individual who was always sharing fun investing stories during class. During our discussion, we talk about what it means to be a fundamentals-based investor, his current hot stock and some advice to beginner investors. This episode is a personal favourite, and we hope you have fun and learn a lot!

    36 min

  7. 05/08/2021

    Health Before Wealth with Marc Wandler

    On today's episode, we have Marc Wandler, the CEO and Co-Founder of Susgrainable, a Vancouver-based health food company. Susgrainable leverages technology and partnerships to create an Upcycled Barley Flour from what was previously considered waste in the beer industry. He is continually redefining what it means to have a sustainable business model with the vision to create a world where food waste and diabetes are a thing of the past. We are excited to hear about Marc's journey and his continued path into developing a circular economy, so let's dive right in!

    47 min

  8. 29/07/2021

    Gold, Bonds and Inflation with Anders Kruus

    We are back with another episode! This week, we are covering a topic that we haven’t discussed before, and one we are not too familiar with ourselves: gold, bonds and inflation. We felt that these topics weren’t talked about enough, and we wanted to provide a resource for those who wanted a breakdown of these topics so we invited Anders Kruus, a knowledgeable industry professional, to educate us on the basics of investing in this space. Feel free to contact Anders at akruus@gmail.com to access more valuable resources!

    42 min
Ver todo (14)

Acerca de

Welcome to Frostbite. Join us as we uncover valuable insights from Canada’s top technology investors, leaders, and innovators. Hosted by Weave VC Co-founder & General Partner, Mark Mitchell. Check out our blog: https://medium.com/@weave.vc Follow us on LinkedIn: https://www.linkedin.com/company/7710458 Connect with us on X: https://twitter.com/WeaveVC

Información

  • Creador
    Mark Mitchell, Co-Founder & General Partner at Weave VC
  • Años de actividad
    2021 - 2023
  • Episodios
    14
  • Clasificación
    Apto
  • Copyright
    © Mark Mitchell, Co-Founder & General Partner at Weave VC
  • Mostrar sitio web
    Frostbite